Chronic Lymphocytic Leukemia

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

Article metrics

Abstract

The eradication of minimal residual disease (MRD) in chronic lymphocytic leukaemia (CLL) predicts for improved outcome. However, the wide variety of MRD techniques makes it difficult to interpret and compare different clinical trials. Our aim was to develop a standardized flow cytometric CLL-MRD assay and compare it to real-time quantitative allele-specific oligonucleotide (RQ-ASO) Immunoglobulin heavy chain gene (IgH) polymerase chain reaction (PCR). Analysis of 728 paired blood and marrow samples demonstrated high concordance (87%) for patients off-therapy. Blood analysis was equally or more sensitive than marrow in 92% of samples but marrow analysis was necessary to detect MRD within 3 months of alemtuzumab therapy. Assessment of 50 CLL-specific antibody combinations identified three (CD5/CD19 with CD20/CD38, CD81/CD22 and CD79b/CD43) with low inter-laboratory variation and false-detection rates. Experienced operators demonstrated an accuracy of 95.7% (specificity 98.8%, sensitivity 91.1%) in 141 samples with 0.01–0.1% CLL. There was close correlation and 95% concordance with RQ-ASO IgH-PCR for detection of CLL above 0.01%. The proposed flow cytometry approach is applicable to all sample types and therapeutic regimes, and sufficiently rapid and sensitive to guide therapy to an MRD-negativity in real time. These techniques may be used as a tool for assessing response and comparing the efficacy of different therapeutic approaches.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4

References

  1. 1

    Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6–14. E-pub 5 July 2002.

  2. 2

    Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU et al. German CLL Study Group. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115–3120.

  3. 3

    Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G et al. German CLL Study Group (GCLLSG). Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093–1101.

  4. 4

    Thieblemont C, Bouafia F, Hornez E, Dumontet C, Tartas S, Antal D et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004; 45: 711–714.

  5. 5

    Milligan DW, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fegan CD et al. National Cancer Research Institute Haematological Studies Group. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 2005; 105: 397–404. E-pub 29 April 2004.

  6. 6

    Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Bruggemann M, Pott C et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600–2602. E-pub 17 June 2004.

  7. 7

    Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079–4088. E-pub 14 Mar 2005.

  8. 8

    Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–4078. E-pub 14 March 2005.

  9. 9

    Bosch F, Ferrer A, Lopez-Guillermo A, Gine E, Bellosillo B, Villamor N et al. For the GELCAB (Grup per l’Estudi dels Limfomes a Catalunya i Balears). Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976–984.

  10. 10

    Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29–35.

  11. 11

    Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228–2235.

  12. 12

    Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971–2979. E-pub 28 February 2005.

  13. 13

    Cabezudo E, Matutes E, Ramrattan M, Morilla R, Catovsky D . Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 1997; 11: 1909–1914.

  14. 14

    Vuillier F, Claisse JF, Vandenvelde C, Travade P, Magnac C, Chevret S et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma 1992; 7: 195–204.

  15. 15

    Moreno C, Villamor N, Colomer D, Esteve J, Gine E, Muntanola A et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563–4569. E-pub 31 January 2006.

  16. 16

    Bottcher S, Ritgen M, Pott C, Bruggemann M, Raff T, Stilgenbauer S et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004; 18: 1637–1645.

  17. 17

    Maloum K, Sutton L, Baudet S, Laurent C, Bonnemye P, Magnac C et al. Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 970–975.

  18. 18

    van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317. Review.

  19. 19

    Cragg MS, Bayne MB, Tutt AL, French RR, Beers S, Glennie MJ et al. A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. Blood 2004; 104: 2540–2542. E-pub 22 June 2004.

  20. 20

    Cragg MS, Bayne MC, Illidge TM, Valerius T, Johnson PW, Glennie MJ . Apparent modulation of CD20 by rituximab: an alternative explanation. Blood 2004; 103: 3989–3990.

  21. 21

    Jilani I, O’Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003; 102: 3514–3520. E-pub 31 July 2003.

  22. 22

    Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245–2247.

  23. 23

    Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 1998; 12: 2006–2014.

Download references

Acknowledgements

Thanks to Florence Cymbalista, Remi Letestu, Sorina Tugulea, Chris Etzler, Fiona Bennett, Ruth de Tute, Brad Dickinson and Ludmila Bezdícková for much appreciated input into the project. This work was supported by Leukaemia Research Fund, UK; AIRC Milano, Italy; MIUR, Italy; National Cancer Institute Grant R21 CA101332 and U10 CA101140, US; Ben Eckenhoff fund, US; Instituto de Salud Carlos III, FIS 04/1051, Spain.

Author information

Correspondence to A C Rawstron.

Additional information

On behalf of European Research Initiative on CLL (www.ericll.org) and the CLL Research Consortium (http://cll.ucsd.edu/)

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • CLL
  • MRD
  • flow cytometry

Further reading